Treatment outcomes of non-small cell lung cancers treated with EGFR tyrosine kinase inhibitors: a real-world cohort study

CONCLUSIONS: EGFR mutants treated with afatinib have improved outcomes compared to gefitinib while later-line osimertinib was applied only for around 20% of the individuals. The study further highlights the good real-world performance of EGFR TKIs and sheds light on therapy sequencing.PMID:37934101 | DOI:10.1080/0284186X.2023.2274481

Source: Acta Oncologica - November 7, 2023 Category: Cancer & Oncology Authors: Otto Manninen Laura Puuniemi Sanna Iivanainen Martti Arffman Riitta Kaarteenaho Jussi P Koivunen Source Type: research